Abstract
PurposeTo compare the feasibility and efficacy of radiofrequency ablation (RFA) combined with chemotherapy and chemotherapy alone in patients with ovarian cancer liver metastasis (OCLM).MethodsIn this retrospective study, a total of 60 patients diagnosed with OCLM between May 2015 to February 2017 were included. All patients with ovarian cancer received chemotherapy and primary cytoreductive surgery before. Thirty patients underwent RFA and chemotherapy, and thirty patients only took chemotherapy. The overall survival (OS), CA-125 levels, and serum AST and ALT levels were compared between the two groups.ResultsIn the RFA group, the 1-,2-, and 3-year OS rates after RFA were 93.3%, 80.0%, and 53.3%, respectively. Serum AST and ALT levels were both elevated after RFA (p=0.0004, p<0.0001). In the chemotherapy group, the 1-,2-, and 3-year OS rates were 79.5%, 60.1%, and 42.1%, respectively. Levels of serum AST and ALT were stable. CA-125 levels for both groups were also available.ConclusionBased on our analysis of a single institution’s series of patients with OCLM, RFA could be a feasibly effective option in the management of OCLM.
Highlights
Ovarian cancer (OC) is the seventh most common cancer and the eighth leading cause of cancerrelated deaths in women worldwide [1]
It is reported that patients with ovarian cancer liver metastasis (OCLM) underwent hepatic resection (HR) within secondary cytoreductive surgery had 3-year post-HR overall survival of 72.9% [7]
There were fifty liver metastases nodules that were ablated in radiofrequency ablation (RFA) group
Summary
Ovarian cancer (OC) is the seventh most common cancer and the eighth leading cause of cancerrelated deaths in women worldwide [1]. A recently published review shows that 5-year OS rates of stage IV ovarian cancer was about 28% [4]. OC metastasis through the intraperitoneal route of dissemination has been recognized as the most common pattern of extraovarian tumor spread, and it may metastasize to distant organs, such as liver, lung, bone, and brain, through hematogenous seeding at the time of diagnosis or during the follow-up [5]. It is reported that patients with ovarian cancer liver metastasis (OCLM) underwent hepatic resection (HR) within secondary cytoreductive surgery had 3-year post-HR overall survival of 72.9% [7]. The unresectable liver metastases conveys a very poor prognosis with a median survival within 1 years due to rapid tumor progression [10]. It is vital for these patients to choose the optimal treatment for liver metastasis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
